LUNG übertreffen die 20 der letzten 21Schätzungen.
95%
Nächster Bericht
Datum des nächsten Berichts
17. Feb. 2026
Estimate forQ4 25(Revenue/ EPS)
$22.16M
/
-$0.39
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+3.07%
/
+14.71%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
-6.74%
/
+18.18%
Pulmonx Corporation Common Stock earnings per share and revenue
On 12. Nov. 2025, LUNG reported earnings of -0.34 USD per share (EPS) for Q3 25, beating the estimate of -0.42 USD, resulting in a 20.32% surprise. Revenue reached 21.50 million, compared to an expected 21.29 million, with a 1.02% difference. The market reacted with a -18.88% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.39 USD, with revenue projected to reach 22.16 million USD, implying an increase of 14.71% EPS, and increase of 3.07% in Revenue from the last quarter.
FAQ
What were Pulmonx Corporation Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Pulmonx Corporation Common Stock reported EPS of -$0.34, beating estimates by 20.32%, and revenue of $21.50M, 1.02% above expectations.
How did the market react to Pulmonx Corporation Common Stock's Q3 2025 earnings?
The stock price moved down -18.88%, changed from $1.96 before the earnings release to $1.59 the day after.
When is Pulmonx Corporation Common Stock expected to report next?
The next earning report is scheduled for 17. Feb. 2026.
What are the forecasts for Pulmonx Corporation Common Stock's next earnings report?
Based on 8
analysts, Pulmonx Corporation Common Stock is expected to report EPS of -$0.39 and revenue of $22.16M for Q4 2025.